A single N66S mutation in the PB1-F2 protein of influenza A virus increases virulence by inhibiting the early interferon response in vivo
- PMID:21084483
- PMCID: PMC3020033
- DOI: 10.1128/JVI.01987-10
A single N66S mutation in the PB1-F2 protein of influenza A virus increases virulence by inhibiting the early interferon response in vivo
Abstract
The PB1-F2 protein of influenza A virus can contribute to viral pathogenesis of influenza virus strains. Of note, an N66S amino acid mutation in PB1-F2 has been shown to increase the pathogenesis associated with H5N1 Hong Kong/1997 and H1N1 Brevig Mission/1918 influenza viruses. To identify the mechanism of enhanced immunopathology, we evaluated the host response to two isogenic viruses that differ by a single amino acid at position 66 of the PB1-F2 protein. Various components of the adaptive immune response were ruled out as factors contributing to pathogenesis through knockout mouse studies. Transcriptional profiling of lungs from PB1-F2 66S-infected mice revealed an early delay in innate immune responses. In particular, enhanced activation of type I interferon (IFN) pathway genes, including IFN-β, RIG-I, and numerous interferon-inducible genes, was not observed until day 3 postinfection. The N66S mutant virus caused increased cellularity in the lungs, as a result of monocyte and neutrophil infiltration. Furthermore, numerous cytokines and chemokines related to monocyte and neutrophil migration and maturation were upregulated. The cellular infiltration and increased cytokine expression corresponded to increased PB1-F2 66S titer. These data suggest that PB1-F2 N66S may contribute to the delay of innate immune responses, allowing for unchecked viral growth and ultimately severe immunopathology observed in the lungs.
Figures





Similar articles
- A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence.Conenello GM, Zamarin D, Perrone LA, Tumpey T, Palese P.Conenello GM, et al.PLoS Pathog. 2007 Oct 5;3(10):1414-21. doi: 10.1371/journal.ppat.0030141.PLoS Pathog. 2007.PMID:17922571Free PMC article.
- The influenza A virus protein PB1-F2: killing two birds with one stone?Varga ZT, Palese P.Varga ZT, et al.Virulence. 2011 Nov-Dec;2(6):542-6. doi: 10.4161/viru.2.6.17812. Epub 2011 Nov 1.Virulence. 2011.PMID:21971186Free PMC article.
- PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models.Hai R, Schmolke M, Varga ZT, Manicassamy B, Wang TT, Belser JA, Pearce MB, García-Sastre A, Tumpey TM, Palese P.Hai R, et al.J Virol. 2010 May;84(9):4442-50. doi: 10.1128/JVI.02717-09. Epub 2010 Feb 24.J Virol. 2010.PMID:20181699Free PMC article.
- Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses.Basler CF, Aguilar PV.Basler CF, et al.Antiviral Res. 2008 Sep;79(3):166-78. doi: 10.1016/j.antiviral.2008.04.006. Epub 2008 May 23.Antiviral Res. 2008.PMID:18547656Free PMC article.Review.
- Influenza A virus PB1-F2 protein: An ambivalent innate immune modulator and virulence factor.Cheung PH, Lee TT, Chan CP, Jin DY.Cheung PH, et al.J Leukoc Biol. 2020 May;107(5):763-771. doi: 10.1002/JLB.4MR0320-206R. Epub 2020 Apr 23.J Leukoc Biol. 2020.PMID:32323899Review.
Cited by
- Influenza virus protein PB1-F2 inhibits the induction of type I interferon by binding to MAVS and decreasing mitochondrial membrane potential.Varga ZT, Grant A, Manicassamy B, Palese P.Varga ZT, et al.J Virol. 2012 Aug;86(16):8359-66. doi: 10.1128/JVI.01122-12. Epub 2012 Jun 6.J Virol. 2012.PMID:22674996Free PMC article.
- In silico thermodynamic stability of mammalian adaptation and virulence determinants in polymerase complex proteins of H9N2 virus.Mosaad Z, Arafa A, Hussein HA, Shalaby MA.Mosaad Z, et al.J Genet Eng Biotechnol. 2018 Dec;16(2):757-767. doi: 10.1016/j.jgeb.2018.02.008. Epub 2018 Feb 23.J Genet Eng Biotechnol. 2018.PMID:30733797Free PMC article.
- Virulent PB1-F2 residues: effects on fitness of H1N1 influenza A virus in mice and changes during evolution of human influenza A viruses.Alymova IV, McCullers JA, Kamal RP, Vogel P, Green AM, Gansebom S, York IA.Alymova IV, et al.Sci Rep. 2018 May 10;8(1):7474. doi: 10.1038/s41598-018-25707-y.Sci Rep. 2018.PMID:29749408Free PMC article.
- Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates.Koday MT, Leonard JA, Munson P, Forero A, Koday M, Bratt DL, Fuller JT, Murnane R, Qin S, Reinhart TA, Duus K, Messaoudi I, Hartman AL, Stefano-Cole K, Morrison J, Katze MG, Fuller DH.Koday MT, et al.PLoS One. 2017 Dec 21;12(12):e0189780. doi: 10.1371/journal.pone.0189780. eCollection 2017.PLoS One. 2017.PMID:29267331Free PMC article.
- An unbiased genetic screen reveals the polygenic nature of the influenza virus anti-interferon response.Pérez-Cidoncha M, Killip MJ, Oliveros JC, Asensio VJ, Fernández Y, Bengoechea JA, Randall RE, Ortín J.Pérez-Cidoncha M, et al.J Virol. 2014 May;88(9):4632-46. doi: 10.1128/JVI.00014-14. Epub 2014 Feb 26.J Virol. 2014.PMID:24574395Free PMC article.
References
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous